about
All that glisters is not gold: a comparison of electronic monitoring versus filled prescriptions--an observational study.Prediction of Glaucomatous Visual Field Progression Using Baseline Clinical Data.Efficacy and safety of femtosecond laser-assisted corneal endothelial keratoplasty: a randomized multicenter clinical trial.Do clinical findings associate with radiographic osteoarthritis of the knee?Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.The relationship between visual field loss in glaucoma and health-related quality-of-life.Detection of Raman spectra in ocular drugs for potential in vivo application of Raman spectroscopy.Economic evaluation of endothelial keratoplasty techniques and penetrating keratoplasty in the Netherlands.Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.Structural and Function Correlation of Cone Packing Utilizing Adaptive Optics and Microperimetry.Axial length and cone density as assessed with adaptive optics in myopia.Correlation of structure and function of the macula in patients with retinitis pigmentosaFacts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review.ICF Core Sets for stroke.Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.Visual Complaints and Eye Problems in Orchestral Musicians.Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review.A review on the design and reporting of studies on drug-gene interaction.Adaptive optics imaging of the outer retinal tubules in Bietti's crystalline dystrophy.Pharmacological management of primary open-angle glaucoma: second-line options and beyond.A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.Quantifying the effect of intraocular pressure reduction on the occurrence of glaucoma.Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber.Differential systemic gene expression profile in patients with diabetic macular edema: responders versus nonresponders to standard treatment.The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis.The influence of the assessment method on the incidence of visual field progression in glaucoma: a network meta-analysis.The evidence base to select a method for assessing glaucomatous visual field progression.The role of the expected value of individualized care in cost-effectiveness analyses and decision making.An evidence-based review of prognostic factors for glaucomatous visual field progression.Ocular hypertension and the risk of blindness.New ophthalmologic imaging techniques for detection and monitoring of neurodegenerative changes in diabetes: a systematic review.Prevention of Cystoid Macular Edema After Cataract Surgery in Nondiabetic and Diabetic Patients: A Systematic Review and Meta-Analysis.A Systematic Review of End-of-Life Visual Impairment in Open-Angle Glaucoma: An Epidemiological Autopsy.Does the World Health Organization criterion adequately define glaucoma blindness?The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma.Predicting intraocular pressure change before initiating therapy: timolol versus latanoprost.High blood pressure and the incidence of non-insulin dependent diabetes mellitus: findings in a 11.5 year follow-up study in The Netherlands.The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.A systematic review on the effect of bevacizumab in exudative age-related macular degeneration: a response to a letter to the editor by Schmucker et al.
P50
Q25255629-D6172C01-5B9D-4300-8471-E9381D2218A5Q30855793-C6BD003F-50A4-4FB8-9DAF-2D594099C829Q30968889-DBF70B20-1B19-4659-BE71-D96BB1757293Q33563030-845B6478-8B65-4025-B9A8-85F0CA79419CQ33669278-F82F7B3F-9CFF-4857-8B32-192D6D62AC5DQ33740609-FA5BAB3C-3AB1-48D2-BBF8-81B86A8AA660Q33964302-13C33EBE-EC41-4D36-B3FE-DEE68D1F5E33Q34249949-2AB814FE-BE85-413F-8939-A4343CFBE1EAQ34557995-0B9D3A85-F8EA-4F8C-B817-3D90C8B337FCQ35705858-146C3954-48C5-4487-ABDA-AB18F19569D3Q35763694-EEC43639-E99B-43DF-8100-96C19C60900BQ35848390-EE8408C4-67B4-4E41-B37F-4F15D80B1302Q35863012-3573B32A-0230-4844-868B-24F74008702DQ35884609-8193970E-DE7D-4C96-AF51-04D0B4EDF292Q35888982-30DACD45-F213-42E8-AB9B-7DC794BAE114Q35904466-C0BE1735-2C86-49DF-83CA-F20EA397FA21Q36116751-F0806B59-44D4-4D66-B57E-CC4E13A45BCFQ36122955-8ACEEE1C-B512-4AD8-A973-4CC91F86C4B6Q36153600-E328D4F3-6529-415D-8184-A556146FFD08Q36906890-2597B809-87C3-4A8B-B5F7-E41C0E442881Q37253030-EC446E7D-0E6E-408B-B37A-82B12DBFD3CAQ37289866-4C42BB9C-FE23-407E-9BE5-7026DC9784DFQ37477336-5D170AE0-D3C0-4DFF-A27D-C536005B3506Q37631954-08505A19-5CEC-4134-95B9-C60E8377DFB2Q37638770-FE13A4CD-9E8A-4E27-9B2F-201DB582E9ACQ37771502-0B6C3B50-6DBC-4344-AC5E-743C7DC5FD60Q37799863-6ABBE248-F0BA-4B4E-A1FE-C787F61C95C3Q37910990-D252D750-FDE0-484A-9887-7795076EA2AAQ37977622-6477CF20-23F0-474E-8485-9804D2B68F75Q38065022-403209E2-78A2-45EB-9AA4-5D9B9DC18658Q38092599-D28330BA-3E45-4C79-BBE4-A3FB87DF4A8CQ38549055-DCA455BC-2FE5-48AD-827E-6E67B804E8F1Q38558794-DD4F0019-8AB3-4332-A08C-5F60CB08C07EQ38743730-7A5468C0-3128-46CE-97EF-C1C7CB7AA2D5Q42318074-2AE6827A-01BA-47DB-8611-B5811777264FQ42634232-C94FDDAA-BFA8-4DE0-B64D-411EE3E4C16CQ42637554-F265F124-C0E1-4B09-8793-724032D99291Q43443352-429D65E1-5717-4EB7-8B6C-00A73DA277C0Q44520157-DB50E4A7-AF34-48FE-A9D5-91CEDD682B5BQ46140886-8A770006-0501-4551-8478-FB25F7B33D13
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Johannes S.a.g. Schouten
@ast
Johannes S.a.g. Schouten
@en
Johannes S.a.g. Schouten
@es
Johannes S.a.g. Schouten
@nl
Johannes S.a.g. Schouten
@sl
type
label
Johannes S.a.g. Schouten
@ast
Johannes S.a.g. Schouten
@en
Johannes S.a.g. Schouten
@es
Johannes S.a.g. Schouten
@nl
Johannes S.a.g. Schouten
@sl
altLabel
J.S. Schouten
@en
prefLabel
Johannes S.a.g. Schouten
@ast
Johannes S.a.g. Schouten
@en
Johannes S.a.g. Schouten
@es
Johannes S.a.g. Schouten
@nl
Johannes S.a.g. Schouten
@sl
P1053
M-9376-2016
P106
P21
P31
P3829
P496
0000-0001-6495-7758